Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 485 shares at $30.10 ($15K) on 2025-09-02, disclosed to the SEC on 2025-09-04.
Scheduled sale ($15k) by Chief R&D Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NKTR | SELL | 2026-06-17 | $336K | — | Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $13K | — | Filing → |